UPMC Trial to Explore Ampligen Combo for Recurrent Ovarian Cancer

UPMC Trial to Explore Ampligen Combo for Recurrent Ovarian Cancer
A new investigator-sponsored clinical trial is recruiting women with recurrent, platinum-sensitive ovarian cancer to study a combination of Hemispherx Biopharma’s investigational product Ampligen (rintatolimod) plus chemo-immunotherapy, the company announced. The Phase 1/2 trial (NCT03734692) is being conducted at the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, under the supervision of Robert Edwards, MD, director of the Ovarian Cancer Program at UPMC Magee Womens Hospital. It is expected to enroll up to 45 adult women who received one or two prior treatments, and responded to platinum-based chemotherapy for six months or longer. “At Hemispherx we are determined to pursue a comprehensive R&D program focused on improved immune therapies for lethal malignancies such as recurrent ovarian cancer,” Thomas K. Equels, CEO of Hemispherx, said in a press release. “We believe this clinical study at UPMC is an important step in Hemispherx’ overall clinical plan in immuno-oncology and just one of the major milestones we have recently announced,” he said. Combination of anti-cancer agents is based on the idea that they can work together to fight cancer. Chemotherapy and immunotherapies such as Merck’s Keytruda (
Subscribe or to access all post and page content.